Life Science Washington released its Life Science News in the NW newsletter for Q4 2023, revealing key industry developments in Washington state.
While many industries including the life sciences, faced economic pressures in Q4, Washington and its startups have continued to fuel innovation. Some of the state’s major moves from the past quarter include:
- Finalization of Pfizer’s $43 billion acquisition of Seattle-based Seagen
- AstraZeneca’s $1.1 billion acquisition of Icosavax, a spinout of the University of Washington
- Seattle Children’s announces BrainChild Bio, a new biotech company focused on cancer therapies for children